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Background: Rheumatoid arthritis (RA) is an inflammatory disease with a
chronic course over many years. Long-term observations in the late 90s have
demonstrated that RA is associated with progressive articular destruction and
increasing disability over the course of the disease. When biologic treatment
was introduced, a lot of studies were able to show a favourable influence on
disease activity, joint destruction, and disability. However, to our knowledge, no
long-term studies have been conducted investigating the radiographic outcome
and disability in this new era of treatment with biologics.
Objectives: To analyse patients with RA for radiographic damage, disability and
disease activity dependent on disease duration.
Methods: We included all RA patients from the Swiss Clinical Quality Management
in rheumatoid arthritis (SCQM) with at least one clinical visit and information
on the disease duration available in the database. The primary endpoint was
the association between the radiographic destruction, assessed by Ratingen
erosion scores at the last clinical visit, and disease duration. This endpoint was
investigated by a multiple negative binomial regression model which corrected
for the effect of gender, age, rheumatoid factor (RF), ACPA and therapeutic
status regarding the use of anti-TNF drugs and methotrexate (MTX), as possible
confounding factors. Disease activity (DAS 28) and disability (HAQ DI) in
dependence of disease duration served as secondary outcomes, analysed by
using a multiple linear regression model with corrections for the same potential
confounders as described for the primary endpoint.
Results: The original 52’753 records on 8’678 patients resulted in 6’526 evaluable
observations for the Ratingen score. Disease duration ranged between less than
1 and more than 65 years, with a median disease duration of 8.3 years,
and past or current use of anti-TNF drugs in 58.4% of patients. We found a
significant association between disease duration and radiographic destruction
with an average increase of Ratingen scores by 8.3% each year (95%CI from
8.1% to 8.6%). The most significant predictor for less radiographic destruction
was a negative rheumatoid factor. During the first 5 years of the disease, clinical
activity and disability decreased over time. While DAS 28-scores remained on a
stable level in patients with a disease duration of more than 5 years (median DAS
28 of 2.8), HAQ-DI scores increased continuously by 0.018 for each additional
year.
Conclusions: In this RA cohort, patients showed a continuous increase of
articular destruction and physical disability in parallel to disease duration, despite
treatment with biologics in the majority of patients. Even though in the era
of biologics a satisfactory control of disease activity can be achieved in most
patients, RA remains a progressive disease leading to joint destruction and
physical disability.
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Background: We have previously shown differential expression of some circu-
lating miRNAs in patients with early RA (ERA) and their potential as markers of
disease activity and treatment response.
Objectives: We aimed to investigate differentially expressed circulating miRNAs
in clinically suspect arthralgia patients with positive antibodies to citrullinated
peptide antigens (ACPA) who are at high risk of developing RA and compared
them to ERA and established RA.
Methods: The study included 20 ACPA+ arthralgia patients, 25 treatment naïve
ERA patients who met the 2010 ACR/EULAR criteria (disease duration <6
months), 26 patients with highly active established RA prior anti-TNF treatment
initiation and 24 healthy controls (HC). Clinical disease activity assessments
(DAS28, SDAI) were performed. Ultrasound of 28 small joints was performed in
ACPA+ arthralgia patients to evaluate subclinical synovitis. Total RNA from plasma
was isolated using phenol-chloroform extraction. A comprehensive analysis of
miRNAs was performed using TaqMan® Low Density Array (TLDA) in 5–6 samples
in each group. The expression of miR-126 was further validated by single assays
in remaining samples and normalized to an average of 2 spike-in C. elegans
controls. dCt was used for relative quantification.
Results: Patients with arthralgia showed no clinical and ultrasound evidence
of arthritis (grey scale and power Doppler for single joint ≤1) Of these, all
were ACPA+, CRP 7.4±19.2 mg/l. Treatment naïve ERA patients had active
disease (DAS28 5.7±1.3, CRP 20.7±23.2 mg/l), 60% were ACPA+. Patients with
established RA all had high disease activity (DAS28 6.6±0.9, CRP 28.1±31.3
mg/l), 73% were ACPA+, had failed DMARDs therapy and were due to commence
anti-TNF treatment. Out of the 380 miRNAs analysed by TLDA, 128 miRNAs
were detected in HC, 129 in arthralgia, 44 in ERA and 25 in RA patients. TLDA
analysis revealed 1.7x higher levels of miR-126 in ACPA+ arthralgia patients
compared to HC, and 27x and 63x lower levels in ERA and RA compared to HC,
respectively. These data were suggestive of significant dysregulation of miR-126
in patients with active polyarthritis compared to ACPA+ arthralgia. However,
further validation showed no difference in miR-126 levels among HC, arthralgia
and ERA patients but the levels were 2.6x lower in RA patients compared to HC
(p=0.0037). The levels of miR-126 significantly negatively correlated with DAS28
(r=-0.460; p=0.047), SDAI (r=-0.535; p=0.018), SJC (r=-0.504; p=0.028), and
TJC (r=-0.517; p=0.023) in treatment naïve ERA patients, but not in those with
established disease. There was no correlation with CRP in any patient group.
Conclusions: Higher miR-126 levels reflect lower disease activity in treatment
naïve ERA patients. We hypothesize that significant downregulation of miR-126
levels in RA patients may be modified by previous exposure to multiple treatments.
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